A Deeper Dive into Advances and Future Directions in Treating Patients with Acute Myeloid Leukemia
A continuing education activity for nurse practitioners, PAs, clinical nurse specialists, advanced degree nurses, oncology and hematology nurses, pharmacists, and physicians.
This activity is supported by unrestricted educational grants from Astellas Pharma Global Development, Inc. and Jazz Pharmaceuticals.
Release date: January 26, 2018 Estimated time to complete activity: 1.5 hour
Expiration date: January 26, 2019
Sandra E. Kurtin, PhDc, ANP-C, AOCN®
The University of Arizona Cancer Center
Gabrielle A. Zecha, PA-C, MHA
The University of Washington
Activity Rationale and Purpose
With an average age at diagnosis of 67 years, AML is primarily a disease of older patients. However, these patients often have trouble tolerating the standard 7 + 3 regimen given to younger patients, so treatment-related mortality becomes a real concern. Also, the natural history of AML appears to be different in older patients, because adverse cytogenetics, antecedent hematologic disorders, and high-risk gene mutations are encountered more frequently. Treatments for patients vary widely depending on age; those younger than 60 frequently receive the standard dose of cytarabine; however, patients older than 60, especially those with comorbid or frail conditions, receive a lower-intensity treatment, with minimal efficacy. This has spurred researchers to look for other treatment options. The field of developmental therapeutics in AML is large, complex, and changing rapidly. A large number of clinical trials are underway nationwide in which alternative regimens are being evaluated. Familiarity with the clinical benefits of these regimens, as well as their side effect profiles, is essential to enable APs to deliver optimal care.
The intended audience for this enduring internet activity is nurse practitioners, PAs, clinical nurse specialists, advanced degree nurses, hematology/oncology nurses, pharmacists, and physicians who specialize in the field of oncology and hematology.
After completing this educational activity, participants should be able to:
- Describe the latest WHO disease definitions for AML
- Recall the mechanism of action for novel therapies for treatment of AML
- Summarize the clinical relevance of molecular mutations in AML, including FLT3 and IDH2
- Identify germline mutations in patients with a predisposition for AML
Statement of Credit—Participants who successfully complete this activity (including the submission of the post-test and evaluation form) will receive a statement of credit.
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education through the joint providership of the Annenberg Center for Health Sciences at Eisenhower, the Advanced Practitioner Society for Hematology and Oncology, and the Journal of the Advanced Practitioner in Oncology. The Annenberg Center is accredited by the ACCME to provide continuing medical education for physicians.
The Annenberg Center for Health Sciences at Eisenhower designates this enduring activity for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Annenberg Center for Health Sciences is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation.
A maximum of 1.5 contact hours may be earned for successful completion of this activity.
Provider approved by the California Board of Registered Nursing, Provider No. 13664, for 1.5 contact hours.
This knowledge-based accredited education lecture is intended for pharmacists involved in the care of cancer patients. This educational activity is sponsored by the Annenberg Center for Health Sciences at Eisenhower.
The Annenberg Center for Health Sciences at Eisenhower is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This program has been assigned ACPE Universal Program # 0797-9999-18-029-H01-P. This program is designated for up to 1.5 contact hours (0.15 CEUs) of continuing pharmacy educational credit.
All individuals in positions to control the content of this activity (eg, planners, faculty, content reviewers) are expected to disclose all financial relationships with commercial interests that may have a direct bearing on the subject matter of this continuing education activity. Participants have the responsibility to assess the impact (if any) of the disclosed information on the educational value of the activity.
Ms. Kurtin has acted as a consultant for Jazz, Celgene, Novartis, Genentech, and Incyte.
Ms. Zecha has nothing to disclose.
Lead Nurse Planner
Dorothy Caputo, MA, BSN, RN, has nothing to disclose.
Jeannine Coronna has nothing to disclose.
Claudine Kiffer has nothing to disclose.
Pamela Hallquist Viale, RN, MS, CS, ANP, has nothing to disclose.
Patricia McLafferty has nothing to disclose.
Chris Cherry has nothing to disclose.
Lynn Rubin has nothing to disclose.
Annie Yueh has nothing to disclose.
Amy Goodrich, Johns Hopkins University, has served on an advisory board for Gilead.
Annenberg Center for Health Sciences at Eisenhower
John Bayliss, VP, Business Development, spouse is an employee of Amgen, Inc.; Charles Willis, Director, Continuing Education, consults for Pfizer Inc.; all other staff at the Annenberg Center for Health Sciences at Eisenhower have no relevant commercial relationships to disclose.
This activity has been designed to provide continuing education that is focused on specific objectives. In selecting educational activities, clinicians should pay special attention to the relevance of those objectives and the application to their particular needs. The intent of the Annenberg Center for Health Sciences, Harborside Medical Education, and JADPRO for all educational opportunities is to provide learning that will improve patient care. Clinicians are encouraged to reflect on this activity and its applicability to their own patient population.
The opinions expressed in this activity are those of the faculty and reviewers and do not represent an endorsement by Harborside Medical Education of any specific therapeutics or approaches to diagnosis or patient management.
This educational activity may contain discussion of published as well as investigational uses of agents that are not approved by the U.S. Food and Drug Administration. For additional information about approved uses, including approved indications, contraindications, and warnings, please refer to the prescribing information for each product.
Statement of Credit: Participants who successfully complete this activity (including scoring of a minimum of 70% on the learning assessment and complete and submit the evaluation form) will be able to download a statement of credit
- 1.50 ANCC
- 1.50 ACPE
- 1.50 AMA PRA Category 1 Credit(s)™
- 1.50 Attendance